How to Test for CIRS: Key Biomarkers and Assessments

Testing for Chronic Inflammatory Response Syndrome involves a layered approach: no single lab value or scan confirms the diagnosis, so clinicians typically combine a functional screening test, a panel of blood-based inflammatory and hormonal biomarkers, genetic typing, and sometimes advanced imaging or molecular profiling. The specific markers involved, from complement proteins and neuropeptides to brain volume measurements, each reveal a different facet of the immune dysregulation that defines CIRS. Understanding what each test actually measures, and what patterns clinicians look for, helps make sense of a diagnostic workup that can otherwise feel overwhelming.

Visual Contrast Sensitivity as a First Screen

Most CIRS evaluations begin with a visual contrast sensitivity (VCS) test, a noninvasive screening tool that measures your ability to distinguish between shades of gray at different spatial frequencies. The test is cheap, quick, and can even be done online. Its logic rests on the observation that biotoxin-related inflammation affects neural pathways involved in vision, particularly the ability to perceive fine gradations of contrast, before obvious symptoms appear in other systems. A recent study comparing four different VCS testing methods in biotoxin-exposed individuals found that contrast sensitivity was significantly reduced in exposed participants on digital VCS tests. The best-performing digital test achieved perfect sensitivity with specificity between 60 and 80 percent, meaning it caught every affected individual while occasionally flagging someone who was actually healthy.¹

An interesting finding from that same study: the original Shoemaker handheld VCS chart, one of the earliest tools used in the CIRS community, did not reliably distinguish between exposed and unexposed groups. Digital versions performed better, which matters if you’re considering an at-home screening test versus one administered in a clinic. A failed VCS test is not proof of CIRS on its own. Eye conditions, neurological disorders, and even dehydration can affect contrast sensitivity. But a positive result, especially in someone with a history consistent with biotoxin exposure, is a useful signal to pursue further bloodwork.

Core Inflammatory Blood Markers

The blood panel most closely associated with CIRS testing revolves around three inflammatory markers: transforming growth factor beta-1 (TGF-β1), complement component 4a (C4a), and matrix metalloproteinase-9 (MMP-9). In a typical CIRS case, at least one of these will be elevated above normal reference ranges.² These markers reflect different aspects of the innate immune system’s overreaction.

TGF-β1 is a cytokine involved in tissue remodeling and immune regulation. When chronically elevated, it is associated with fibrosis, autoimmune-like responses, and a range of downstream effects. MMP-9, an enzyme that breaks down components of connective tissue, rises during active inflammation and has been linked to increased permeability of barriers like the blood-brain barrier. C4a is a split product of the complement system, part of the body’s ancient first-response defense network, and its elevation signals ongoing immune activation of a specific type.

These markers are ordered from standard commercial labs, not specialty tests. The important thing is that a single elevated marker does not tell the whole story. Clinicians typically look for a pattern across multiple markers combined with symptoms and exposure history. A person with high TGF-β1 and MMP-9, low MSH (discussed below), and a known history of living in a water-damaged building presents a very different picture from someone with an isolated elevation in one marker.

What Complement Patterns Reveal About Exposure

Within the complement system, C4a and C3a can be ordered together, and the pattern of which is elevated gives clinicians a clue about the type of biotoxin exposure involved. When C4a is elevated but C3a is normal, the most likely trigger is exposure to a water-damaged building. When both C4a and C3a are elevated together, the picture shifts toward tick-borne illness, or a combination of tick-borne illness and water-damaged building exposure.³

C3a can also be elevated in acute Lyme disease, so that possibility needs to be excluded before interpreting a high C3a reading as part of the CIRS pattern.³ This is one of the reasons CIRS testing cannot be read in isolation from the clinical context. A complement split product elevation means something different depending on what else is going on in the patient’s history and bloodwork.

Neuropeptide and Hormonal Markers

One of the hallmarks of CIRS is the suppression of regulatory neuropeptides, particularly melanocyte-stimulating hormone (MSH) and vasoactive intestinal polypeptide (VIP). These are not exotic research molecules; they play active roles in controlling inflammation, regulating hormones, and maintaining the integrity of mucosal barriers throughout the body. In CIRS patients, MSH is typically low, and this deficiency has been documented in over 98 percent of patients in clinical samples.⁴ When MSH drops, the body loses a key brake on innate immune activity, which helps explain why symptoms can persist long after the original biotoxin exposure ends.

VIP deficiency follows a similar pattern. In a clinical trial, VIP replacement therapy safely corrected inflammatory markers including C4a, TGF-β1, VEGF, and MMP-9, and also normalized hormonal values like estradiol, testosterone, and vitamin D levels.⁴ This finding underscores why VIP and MSH levels are included in the diagnostic panel: they sit upstream of many of the other abnormalities, and their deficiency is a central feature of the condition rather than a secondary consequence.

Beyond the neuropeptides, several hormonal axes are commonly dysregulated in CIRS. These are tested through standard blood draws:

ACTH and cortisol: The stress hormone axis can show a mismatch, with ACTH and cortisol failing to track each other normally.
ADH and osmolality: Antidiuretic hormone and blood osmolality may be out of sync, contributing to symptoms like excessive thirst, frequent urination, and susceptibility to static shocks.
VEGF: Vascular endothelial growth factor, involved in blood vessel formation and oxygen delivery to tissues, can be abnormally high or low.
Antigliadin antibodies: These may be elevated without the person having celiac disease, suggesting immune reactivity driven by the broader inflammatory process.
Anticardiolipin antibodies: Elevated levels can indicate autoimmune-like activity affecting blood clotting pathways.

All of these can be measured through national commercial laboratories, not specialty research labs.² The clinical value lies in the constellation. An isolated abnormal ADH level might mean nothing; an abnormal ADH combined with low MSH, elevated C4a, and a failed VCS test starts to build a recognizable picture.

HLA Genetic Testing for Susceptibility

A genetic test that frequently shows up in CIRS evaluations looks at your HLA-DR and HLA-DQ alleles. These genes encode proteins on the surface of immune cells that help the body recognize and clear foreign substances, including biotoxins like mycotoxins from mold. Certain HLA types are associated with a reduced ability to properly tag and eliminate these toxins, making carriers more vulnerable to chronic illness after exposure.⁵

This test is done from a standard blood sample and only needs to be run once, since your HLA type does not change over your lifetime. It does not diagnose CIRS directly. Rather, it tells you whether you carry a genetic profile that makes you a “poor eliminator” of certain biotoxins, meaning your immune system may not clear them efficiently the way most people’s does. Roughly a quarter of the general population carries at least one of the susceptible HLA haplotypes, which helps explain why one person living in a water-damaged building gets severely ill while another sharing the same space feels fine.

The practical value of HLA testing is mostly in context-setting. If you carry a susceptible haplotype and your inflammatory markers are elevated, the genetic result supports the clinical picture. If your HLA type is not one of the susceptible ones, it does not rule out CIRS, but it does make the diagnosis less straightforward and prompts a closer look at other potential triggers.

NeuroQuant Brain MRI

For patients whose symptoms are heavily neurological, such as difficulty with word-finding, memory problems, disorientation, or chronic headaches, some clinicians order a brain MRI analyzed with NeuroQuant, a software program that measures the volume of specific brain structures and compares them to age-matched norms. In a study of patients with inflammatory illness linked to water-damaged buildings, NeuroQuant analysis revealed statistically significant abnormalities compared to a control group. Patients showed atrophy of the caudate nucleus and enlargement of the pallidum in both hemispheres, along with enlargement of the left amygdala and right forebrain.⁶

These volumetric changes, when found alongside the elevated inflammatory markers described above, suggest a model where chronic systemic inflammation increases the permeability of the blood-brain barrier, allowing inflammatory molecules to affect brain tissue directly.⁶ The practical limitation is that NeuroQuant analysis is not universally available, and a standard MRI read by a radiologist without the software will typically come back “normal” because the volume changes are subtle and pattern-specific. You need a facility that runs the NeuroQuant software or a clinician willing to order it specifically.

This is not an early screening test. It tends to come later in the diagnostic process, either to document the extent of neurological involvement or to track treatment progress over time. Some patients see measurable improvement in brain volumes after treatment, which can serve as objective evidence of recovery when symptoms alone are hard to quantify.

Transcriptomic Profiling and the GENIE Platform

The most recent addition to the CIRS diagnostic toolkit is transcriptomic profiling, which examines gene expression patterns in whole blood rather than measuring individual protein levels. The development of this approach has been traced from early RNA sequencing research between 2015 and 2017 to the creation of a clinical platform called GENIE (Gene Expression: Inflammation Explained), which uses targeted molecular barcoding technology to measure the activity of specific genes involved in immune regulation and metabolism.⁷

GENIE profiles are interpreted using standardized scores derived from a healthy reference population, which anchors the results against what normal gene expression looks like. The platform can detect patterns of molecular hypometabolism, immune dysregulation, and cellular structural damage at a level that traditional blood markers cannot reach. It can also potentially identify the likely environmental trigger behind a patient’s CIRS, whether from a water-damaged building, a tick-borne illness, or another biotoxin source.⁷

This is where the science is heading, but access remains limited. Transcriptomic testing is not part of routine clinical medicine, and insurance coverage for it is inconsistent at best. For most people being evaluated for CIRS right now, the standard blood panel, VCS testing, and HLA typing form the backbone of the workup. GENIE and similar molecular tools represent a deeper layer of investigation that can be valuable for complex cases, particularly those where symptoms overlap heavily with other chronic conditions like myalgic encephalomyelitis/chronic fatigue syndrome and the traditional markers are ambiguous.

Why Standard Lab Work Often Comes Back “Normal”

One of the most frustrating aspects of CIRS for patients is that conventional medical screening, the kind done during an annual physical, almost always looks fine. A complete blood count, basic metabolic panel, thyroid panel, and standard inflammatory markers like CRP or ESR are typically within normal limits. This happens because CIRS involves parts of the immune and hormonal systems that standard panels do not measure. C4a, TGF-β1, MMP-9, MSH, VIP, and ADH are not included in routine bloodwork. Neither is HLA typing. A doctor unfamiliar with CIRS may order standard labs, find nothing wrong, and conclude that the patient’s symptoms are unexplained or psychosomatic.

This gap between what routine labs test and what CIRS affects is the single biggest reason the condition goes undiagnosed. If you suspect CIRS based on your symptoms and exposure history, the specific biomarker panel described above needs to be requested by name. Some of these tests, like C4a, also have handling requirements (the sample needs to be processed and frozen quickly), which means not every local lab draws them correctly. Specialty labs or specific Quest and LabCorp protocols may be necessary, and a clinician experienced with CIRS will know which tests require special handling.

Putting the Pieces Together

CIRS testing is inherently pattern-based. No single biomarker, gene, or scan makes the diagnosis. Clinicians who work with these patients typically look for convergence across multiple lines of evidence: a plausible exposure history, symptoms affecting multiple organ systems, a failed VCS test, characteristic abnormalities across the inflammatory and hormonal blood panel, and ideally supportive findings from HLA typing or neuroimaging. The diagnosis gains strength with each additional piece of the pattern that fits.

The order in which tests are done also matters practically. VCS testing and the core blood panel (including C4a, TGF-β1, MMP-9, MSH, VIP, ADH/osmolality, ACTH/cortisol, VEGF, and antibody markers) are usually the starting point because they are the most accessible and informative. HLA testing follows if the clinical picture is consistent, since it adds context about genetic vulnerability. NeuroQuant and transcriptomic profiling come later, reserved for cases that need more documentation, face diagnostic ambiguity, or need to differentiate CIRS from conditions with overlapping symptoms. The testing process is sequential and additive rather than a single decisive moment, which can feel slow when you are the person waiting for answers, but each layer genuinely adds information the previous one could not provide.

1
PubMed Central. Assessment of visual contrast sensitivity in biotoxin-exposed individuals using four testing methods
2
Annals of Medicine and Surgery. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment
3
Medical Research Archives. The CIRS Protocol: A Sequential, Evidence-Based Treatment for Biotoxin-Associated Chronic Inflammatory Response Syndrome
4
Health. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings
5
PubMed. HLA gene variations and mycotoxin toxicity: Four case reports
6
PubMed. Structural brain abnormalities in patients with inflammatory illness acquired following exposure to water-damaged buildings: a volumetric MRI study using NeuroQuant®
7
International Journal of Molecular Sciences. Biomarkers over Time: From Visual Contrast Sensitivity to Transcriptomics in Differentiating Chronic Inflammatory Response Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome